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Abstract
Objective. Neutrophil elastase is secreted by neutrophils during activation and circulates in the plasma
where it can play a role in inflammation and fibrosis. This study examines the role of neutrophil elastase in
SSc, a systemic CTD that is typified by vascular dysfunction, tissue fibrosis and inflammation.
Methods. Serum neutrophil elastase and a1-anti-trypsin concentrations were assessed in SSc patients
and healthy controls by ELISA. Serum neutrophil elastase activity was assessed by the elastase-
dependent conversion of methoxy-succinyl-alanyl-alanyl-prolyl-valyl-p-nitroanilide to p-nitroanilide using
a colourimetric assay. Elastase concentration and activity were correlated with clinical disease features.
Results. Serum neutrophil elastase concentration and activity were equivalent in patients and controls;
however, in SSc serum, there was an increase in elastase activity for each unit of elastase concentration
(P=0.03). This was due to a decrease in serum a1-anti-trypsin concentrations (P=0.04). Serum elastase
concentration (P=0.03) and activity (P=0.02) were significantly lower in RNP-positive patients and serum
elastase concentrations were lower in ANA-positive patients (P=0.003).
Conclusions. Relative deficiency in serum a1-anti-trypsin concentrations in SSc could have important and
pathogenically relevant effects since elastase has pro-inflammatory and pro-fibrotic roles. Elastase inhibi-
tors are available in clinical practice and could represent potential therapeutic options in SSc.
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Introduction
Neutrophil elastase is a serine protease that is stored in
the azurophilic granules of neutrophils. It predominantly
functions as an intracellular anti-microbial protein and is
released into the phagolysosome following phagocytosis
to mediate bacterial digestion. However, in addition, it is
secreted by the cell. In the extracellular space, neutrophil
elastase has additional functions in the regulation of in-
flammation and it is implicated in inflammatory and fibrotic
conditions, including fibrotic lung disease [1, 2]. Elevations
in serum elastase have previously been reported in pa-
tients with SSc where it was associated with lung
disease [3].
Serum elastase activity is regulated by serine protease
inhibitors. The main intracellular inhibitor of elastase is
serpin peptidase inhibitor clade B member 1 (SERPIN
B1), whereas the main extracellular inhibitor of neutrophil
elastase is a1-anti-trypsin and additional inhibition is
mediated by a2-macroglobulin, elafin and secreted leuco-
cyte proteinase inhibitor (SLPI) [4]. Neutrophil elastase can
also be expressed on the neutrophil membrane, where it
occupies low- and high-affinity binding sites. Membrane
expression is increased by neutrophil activation with cyto-
kines such as TNF-a and IL-8 [5]. The increase in mem-
brane expression is more significant than the amount
secreted extracellularly during typical activation. Plasma
membrane-bound elastase has the same catalytic func-
tions as soluble elastase, but there is some evidence that
the membrane-bound enzyme is relatively resistant to a1-
anti-trypsin [6, 7].
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increased in lesional biopsies of SSc patients compared
with controls [8]. Others have explored neutrophil function
in SSc, in particular their ability to contribute to oxidative
stress by the production of reactive oxygen species. The
data are contradictory and largely limited by old-fashioned
neutrophil isolation procedures that can lead to neutrophil
activation [9, 10]. A recent study has, however, shown that
neutrophils produce less reactive oxygen species in vitro
compared with control neutrophils when unstimulated
[11]. In agreement with this we have found that neutrophils
from patients with SSc are hypofunctional in tests of
reactive oxygen species generation and chemotaxis
(unpublished data). This may reflect in vivo stimulation,
and hence in vitro exhaustion. Proteomic studies show
that SSc neutrophils have increased expression of
proteins that are also increased on stimulation with lipo-
polysaccharide or TNF, again indicative of neutrophil ac-
tivation in vivo (unpublished data).
Since neutrophil elastase has established roles in other
inflammatory and fibrotic disorders, we hypothesized
that neutrophil elastase could be an important mediator
in the pathogenesis of SSc. To explore this hypothesis,
the concentration and catalytic activity of neutrophil elas-
tase in SSc serum was compared with controls. In add-
ition, the membrane expression of elastase was measured
in SSc neutrophils compared with controls, and clinical
correlates were studied.
Methods
The study was approved by the Sefton Local Research
Ethics Committee, in accordance with the Declaration of
Helsinki. Informed written consent was taken from pa-
tients with SSc [12] and from healthy volunteers. Thirty
millilitres of heparinized venous blood were taken from
the subjects. Peripheral blood was separated into neutro-
phil and mononuclear cell fractions using Polymorphprep
(as described in the manufacturer’s instructions).
Contaminating erythrocytes were removed using ammo-
nium chloride lysis buffer (KHCO3 3.4mM, NH4Cl 155mM
and EDTA 96.7mM). Neutrophils were routinely examined
for purity using morphological analysis of cytospins after
staining with Rapid Romanowsky: purity was >95% im-
mediately after isolation. Neutrophils were resuspended
in Roswell Park memorial institute (RPMI) 1640+25mM
4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid
(HEPES)+2mM glutamine at a concentration of
510
6cells/ml.
Serum elastase concentrations
Neutrophil elastase and a1-anti-trypsin levels were mea-
sured in SSc patient and control serum using a PMN elas-
tase ELISA (Bender, Vienna) and an a1-anti-trypsin ELISA
(Abnova, Taipei), respectively, according to the manufac-
turer’s instructions. The intra- and interassay coefficients
of variation for the PMN elastase ELISA were 4.8 and
5.6%, respectively, with standard range 0.1610ng/ml
and sensitivity 1.98ng/ml. The epitope for the PMN elas-
tase ELISA is unknown and it is unknown whether both
active and inactive enzymes are detected using this
assay. The intra- and interassay coefficients of variation
for the a1-anti-trypsin ELISA were 4.2 and 7.1%, respect-
ively, with standard range 0.03940mg/ml and sensitivity
20ng/ml.
Neutrophil elastase concentrations in neutrophil
culture supernatants
Neutrophils were isolated from SSc and healthy control
blood, and were cultured for 6h with gentle agitation at
37C at a density of 10
7cells/ml in RPMI 1640+25mM
HEPES+2mM glutamine. Cells were precipitated by cen-
trifugation (1000g for 5min) and the neutrophil elastase
concentration in the supernatants was measured by
ELISA (Bender, Vienna).
Serum neutrophil elastase enzymatic activity
Following experiments to optimize substrate concentra-
tion and length of incubation, serum elastase activity was
measured using a colourimetric assay. In 96-well clear
plastic plates, 150ml of elastase buffer (0.1M HEPES,
0.5M NaCl, pH 7.5) was added to 50-ml serum sam-
ples from patients with SSc and healthy controls. The
substrate (15mM methoxy-succinyl-alanyl-alanyl-prolyl-
valyl-p-nitroanilide) was added to a final concentration of
750mM. The reaction was incubated in the dark at 37C
for 6h. The elastase-dependent conversion of colourless
methoxy-succinyl-alanyl-alanyl-prolyl-valyl-p-nitroanilide
to yellow p-nitroanilide was measured as a change of ab-
sorbance at 405nm on a plate reader. Standards of
known concentration were used to generate a calibration
curve (data not shown). The intra- and interassay
co-efficients of variation were 1.2 and 6.8%, respectively.
Clinical data
Clinical data were collected on all patients as a part of rou-
tine clinical care and included Rodnan skin score, neutro-
phil count, autoantibody profile, medications, major organ
involvement and disease duration (defined as time since
onset of first non-Raynaud’s symptom). Pulmonary artery
hypertension was confirmed by right heart catheterization.
Pulmonary fibrosis was diagnosed according by pulmon-
ary function tests and high resolution computed tomogra-
phy (HRCT), subdivisions for severity were not applied.
Neutrophil membrane elastase expression
Neutrophil membrane elastase expression was measured
by flow cytometry. Neutrophils were isolated from SSc
and healthy control blood as previously described. Cells
were resuspended in 200ml of phosphate buffered saline
(PBS) 2% BSA, and incubated for 30min in the dark at
4C with 2ml elastase monoclonal antibody raised in rabbit
(Calbiochem), following experiments to find the optimal
antibody dilution (data not shown). The cells were
washed three times in PBS and resuspended in PBS
2% BSA and 2ml FITC-conjugated anti-rabbit IgG second-
ary antibody. Cells were incubated for 30min at 4C in the
dark. Cells were washed three times in PBS, resuspended
in PBS and analysed on the flow cytometer on the FITC
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secondary antibody control.
Statistical methods
The data were non-normally distributed and were there-
fore compared using the MannWhitney U-test.
Results
Clinical characteristics
Table 1 shows the clinical characteristics of the SSc
patients.
Serum neutrophil elastase levels were equivalent in
patients with SSc compared with controls
There was no significant difference between SSc patient
and control serum levels of neutrophil elastase (P=0.11)
(Fig. 1A).
Neutrophil elastase concentrations in control and SSc
neutrophil culture supernatants are equivalent
There was no difference in the levels of neutrophil elastase
in supernatants following a 6-h culture of control and SSc
neutrophils in RPMI 1640+25mM HEPES+2mM glutam-
ine (P=0.53).
Serum neutrophil elastase activity is equivalent in SSc
patients and controls
The serum neutrophil elastase activity was measured in
SSc patients and controls by the elastase-dependent
conversion of methoxy-succinyl-alanyl-alanyl-prolyl-valyl-
p-nitroanilide to p-nitroanilide. No difference in serum
elastase activity was found between SSc patients and
controls (P=0.91) (Fig. 1B). However, there was a propor-
tion of patients [6/18 (33%)] that had high serum elastase
activity (>0.15U/ml) compared with 1/9 (11%) controls.
These patients had either early disease <36 months or a
higher Rodnan skin score of >9. There was a significant
decrease in the ratio of serum elastase concentration:
activity (P=0.03) (Fig. 1C). There were no distinguishing
clinical features in the patients with a low serum elastase
concentration:activity ratio (<50000).
Clinical correlations with serum neutrophil elastase
concentration and activity
Disease subtype, disease duration, major organ involve-
ment, neutrophil count or DMARD use did not correlate
with either serum neutrophil elastase concentration or activ-
ity. Serum elastase concentration was significantly lower in
RNP and ANA-positive patients compared with antibody-
negative patients (P=0.03 and P=0.003, respectively). In
addition, serum elastase activity was significantly lower in
RNP antibody-positive patients (P=0.02).
Membrane expression of neutrophil elastase
No difference was found in the membrane expression of
neutrophil elastase between SSc and control neutrophils.
Serum a1-anti-trypsin
Serum a1-anti-trypsin concentrations were significantly
lower in SSc patients compared with controls (P=0.04,
n=20) (Fig. 1D).
Discussion
In this study, we identified no difference in serum elastase
concentration or catalytic activity in SSc patients com-
pared with controls. This contradicts a previous study by
Hara et al. [3], which observed an increase in serum elas-
tase concentration in both limited and diffuse SSc pa-
tients. However, an examination of their data reveals
that the serum elastase levels measured in this study
were similar in magnitude and variation to their obser-
vations in SSc patients. In this study, however, higher
serum elastase concentrations and greater variance in
concentration were found in the control cohort, whereas
the previous study showed consistently low levels in all
controls. The previous study did not examine elastase
activity.
Hara et al. [3] also reported that serum elastase levels
were more likely to be outside the normal range in patients
with joint involvement, and they observed that most pa-
tients who were ACA positive were likely to have normal
levels of elastase. We did not record joint involvement as
a clinical outcome in our cohort. It is interesting to note,
however, that we observed lower serum elastase levels in
RNP-positive patients, since these patients would be
expected to have higher rates of joint involvement. Hara
et al. [3], did not record RNP antibody status in their study.
TABLE 1 Patient characteristics
Clinical feature
Median
Interquartile range
Disease duration, months 40 (2196)
Neutrophil count10
9/l 4 (2.44.8)
Rodnan skin score 6 (310)
n/N (%)
Limited SSc 29/33 (88)
Diffuse SSc 4/33 (12)
ANA 26/31 (84)
Anti-centromere 13/31 (42)
Anti-RNP 9/31 (29)
Anti-Scl70 9/31 (29)
Lung involvement 10/33 (30)
Pulmonary artery hypertension 5/33 (15)
DMARDs 14/33 (42)
HCQ 3/33 (9)
MMF 4/33 (12)
MTX 1/33 (3)
CYC 1/33 (3)
PRED 3/33 (9)
AZA 1/33 (3)
Bosentan 1/33 (3)
Sildenafil 3/33 (9)
PRED: prednisolone.
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a1-Anti-trypsin in SScIt would be interesting to correlate the data with anti-RNA
polymerase III expression as this antibody can be asso-
ciated with inflammatory skin disease; however, we do not
routinely perform this autoantibody on our patients.
It may seem somewhat surprising that Hara et al. [3]
described such an increase in serum elastase levels,
since only 2% of serum elastase is released during neu-
trophil activation and raised serum levels are usually only
found in situations where there is pronounced neutrophil
infiltration, frustrated phagocytosis or excess neutrophil
apoptosis, which overwhelms phagocytic clearance
[5, 13, 14]. As none of these is implicated in SSc, we
would not expect to find elevated serum levels, an expect-
ation confirmed in our studies. Certainly, direct observa-
tions do not show significant neutrophilic infiltration and
there is no evidence of excessive neutrophil apoptosis.
CRP at the time the assays were collected was normal
in all but five patients. The mean CRP was <5 (where 5 is
the lower limit of detection in the assay used). Of the five
patients with elevated CRP, none of these had an elevated
serum elastase nor were they patients with a low serum
a1-anti-trypsin. One of these patients, with a CRP of 8, did
have a low serum elastase concentration:activity ratio
(<50000); however, the others (CRP 819) did not.
We did not observe any increase in the membrane
expression of elastase on SSc neutrophils. Secretion of
azurophilic granule contents during degranulation or acti-
vation by cytokines results in the increased expression
of neutrophil elastase at the membrane. Therefore, this
observation argues against significant degranulation of
the azurophilic granules in SSc neutrophils [5].
We did observe a decrease in the ratio of elastase
concentration:activity in SSc serum. This may imply a
decrease in the serum concentration or activity of neutro-
phil elastase inhibitors. This was confirmed by a decrease
in serum a1-anti-trypsin concentrations in SSc patients,
which is the main inhibitor of elastase function in the
serum. In addition, serum elastase inhibitors can be oxi-
dized in the presence of ROS and this decreases their
affinity for elastase, reducing their inhibitory capacity
[15, 16]. There is evidence for increased oxidative stress
in SSc [17].
The stoichiometry of the interaction between a1-anti-
trypsin is 1:1 and the inhibition of elastase is linear for
FIG.1Elastase and a1-anti-trypsin were measured in SSc and control serum by ELISA, serum elastase activity was
measured by the elastase-dependent conversion of methoxy-succinyl-alanyl-alanyl-prolyl-valyl-p-nitroanilide to
p-nitroanilide. No difference was found in serum elastase concentration (A) or activity (B). There was a significant
decrease in the ratio of elastase concentration:elastase activity in SSc serum compared with controls (C): this was
due to a decrease in serum a1-anti-trypsin concentration in SSc serum compared with controls (D).
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Simultaneous measurements of a1-anti-trypsin and elas-
tase were not taken in this study, and therefore the molar
ratios in these patients cannot be derived. However, in
this disease, it is unlikely to be the serum molar ratios
that are relevant rather the local tissue levels. Tissue
levels of a1-anti-trypsin are likely to be dictated by the
serum concentration since it is produced by the liver
and not produced distally [4]; however, the molar concen-
tration of elastase is likely to be dictated locally where, for
instance, interaction of neutrophils with activated endo-
thelium and pro-inflammatory cytokines may lead to elas-
tase release.
Neutrophil elastase has pleiotropic roles in the extracel-
lular environment including profound effects on inflamma-
tion [1, 2]. Neutrophil elastase activates and degrades
inflammatory cytokines, regulates neutrophil attachment,
activates proteinase-activated receptor 2 (PAR-2) leading
to the release of IL-8 and macrophage chemotactic
factor-1, activates toll-like receptor-4 leading to the re-
lease of IL-8, cathepsin B and MMP-2. Elastase can
cleave TNF p75 receptor and IL-6R from cells leading to
an increased pool of soluble receptor. This in turn leads to
inactivation of soluble TNF-a but increased IL-6
trans-signaling. Elastase can cleave the phosphatidylser-
ine receptor, leading to defects in the phagocytic clear-
ance of apoptotic cells and can enter endothelial cells,
where it cleaves nuclear factor kappa B leading to
endothelial cell apoptosis.
Although the role of neutrophil elastase in fibrosis is well
established, the mechanism remains unclear. Certainly,
elastase-deficient mice are resistant to bleomycin-
induced fibrosis and treatment with elastase inhibitors
also abolished fibrosis in this model [1821]. Neutrophil
elastase can cleave TGF-b-binding protein leading to re-
lease of latent TGF-b from extracellular matrix stores [22].
It has also been shown to release PDGF and VEGF from
stores by a similar mechanism [23]. All of these cytokines
are implicated in the pathogenesis of SSc; TGF-b and PDGF
are pro-fibrotic and VEGF is pro-angiogenic. Neutrophil
elastase has other roles in promoting the activity of TGF-b.
Intra-tracheal instillation of elastase in mice leads to a
time-dependent increase in the TGF-b content of the bron-
choalveolar lavage fluid [24]. In elastase-deficient mice,
the resistance to bleomycin is associated with an inability
to activate TGF-b [18].
It is interesting that serum elastase concentrations and
activity are lower in RNP-positive patients. This may imply
that there is a different pathological process involved
in RNP-positive patients and that neutrophil elastase is
unlikely to be a significant mediator in these patients.
In fact, serum elastase concentrations were lower in
RNP-positive patients than controls (P=0.008). This may
represent an accelerated loss of neutrophil elastase in
RNP-positive patients.
Analysis of the literature shows that neutrophil elastase
could be an attractive mediator in SSc. It can promote
chronic inflammation and TGF-b-dependent fibrosis, and
cause endothelial cell apoptosis. Serum deficiency in
elastase inhibitors could lead to a localized excess of
elastase activity despite normal serum concentrations.
This could have potential therapeutic implications as neu-
trophil elastase inhibitors already exist in clinical practice
and could be used in SSc patients.
Rheumatology key message
. a1-Anti-trypsin is decreased in serum of patients
with SSc and may contribute to inflammation and
fibrosis.
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